Procter & Gamble Tops Expectations

Procter & Gamble Tops Expectations

Procter & Gamble, the consumer goods firm with brands including Charmin, Downy and Pampers, topped analysts’ expectations in the “difficult operating environment” of the fiscal second quarter, but revenue fell from a year earlier. Core earnings per share were $1.08 for the period ending Dec. 31, up four cents from a year ago and two cents above the consensus view on Capital IQ. Revenue slipped to $16.86 billion from $16.92 […]

Read More ˃
TAL Education Tops Estimates On Fiscal Q3 EPS And Revenues

TAL Education Tops Estimates On Fiscal Q3 EPS And Revenues

TAL Education American depository shares were higher 3% in recent pre-market trade after the tutoring services provider in China reported fiscal Q3 adjusted earnings per ADS of $0.26, up from $0.19 in the same period a year ago and topping the estimate of $0.22 from analysts polled by CapIQ. For the quarter ended Nov.30 total revenues of $260.6 million were up from $142.2 million in the same period a year […]

Read More ˃
Netflix Signs Comedian Jerry Seinfeld to Production Deal

Netflix Signs Comedian Jerry Seinfeld to Production Deal

Netflix said it signed comedian Jerry Seinfeld to a multi-faceted production deal that will include new episodes of ‘Comedians in Cars Getting Coffee’ and two new stand-up specials. Financial terms of the agreement weren’t disclosed. The video streaming company said the first all-new stand-up show will become available later this year. Netflix also said Seinfeld will develop scripted and non-scripted comedy programming for the company, with additional elements to be […]

Read More ˃
Astrazeneca Refines Endpoints in Phase III MYSTIC Trial

Astrazeneca Refines Endpoints in Phase III MYSTIC Trial

Astrazeneca Tuesday provided an update on its Immuno-Oncology (IO) late-stage clinical development programme in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the phase 3 MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) chemotherapy, focused on progression-free survival (PFS). The company says that the MYSTIC trial will now assess […]

Read More ˃
Goldcorp Seeks to Join Hands With Rivals

Goldcorp Seeks to Join Hands With Rivals

Goldcorp’s search for growth in the future will likely target partnerships with rivals as it considers spreading out the task of developing multibillion-dollar projects, according to a report from Bloomberg TV Canada that cited the company’s CEO as saying. Shares drifted slightly higher intraday. The interest has largely been in large-scale projects in North and South America, David Garofalo was cited as saying in the news report. The report said […]

Read More ˃